Market Research Logo

Molecular Cytogenetics Market Analysis by Technology (FISH and CGH), by Application (Genetic Disorders, Cancer, Personalized Medicines) and Segment Forecasts To 2022

Molecular Cytogenetics Market Analysis by Technology (FISH and CGH), by Application (Genetic Disorders, Cancer, Personalized Medicines) and Segment Forecasts To 2022

Global molecular cytogenetics market is expected to reach nearly USD 3.6 billion by 2022, according to a new report by Grand View Research, Inc.

Increasing instances of both, chromosomal anomalies implicated in genetic disorders and cancer, coupled with technological advancements in the molecular cytogenetic techniques is expected to positively reinforce the market growth.

Technological advancements in molecular diagnostic techniques, such as the Fluorescence In-situ Hybridization (FISH) and the Comparative Genomic Hybridization (CGH) are enabling rapid analysis of patient data to identify the potential risk factors. Increasing applications of FISH and CGH in molecular diagnostics are expected to propel the market growth in the next seven years.

The advent of the genome wide screening technique, the Next Generation Sequencing (NGS) technology enables the detection of a number of chromosomal variations in parallel by comparing genomic sequences of patient and control samples.

The NGS technique empowers the clinicians in taking therapeutic decisions based on in-depth information regarding an individual’s genetic profile; and hence, the introduction of such technologies is expected to positively reinforce the market growth during the forecast period. Initiatives such as the precision medicine initiative announced by the U.S. president are expected to further drive the demand for the molecular cytogenetic tests.

In 2014, the CGH in the technology segment held the maximum market share of 52% owing to enhanced technical specifications such as high speed, accuracy, and high resolution images as compared to the FISH technology. Furthermore, the CGH technology is also expected be the fastest growing segment with a lucrative CAGR of nearly 26% over the forecast period.

In 2014, the application of molecular cytogenetics in cancer held the largest market share of over 42%. The high demand for preventive screening and diagnosis, which significantly aids the early detection of risk factors that lead to oncogenesis, are amongst the key factors responsible for the cancer segment’s high share. Cancer was followed by the personal medicine segment with a market share of over 23%. In conclusion, the cancer segment is expected to be the fastest growing market with a high CAGR of 24.1% over the forecast period.

Further key findings from the study suggest:

In 2014, North America held the largest market share of 47.6%. The large share is attributed to the presence of high-tech R&D facilities, well established manufacturing infrastructure, and active collaborations between private stakeholders, such as technology companies, research centers, universities, patients, as well as government agencies such as the U.S. FDA and CDC that ensure that the new technologies are validated.

Asia Pacific is expected to witness lucrative CAGR of nearly 26% in the next seven years owing to the high unmet medical needs such as the increasing prevalence of cancer, genetic, and other hereditary diseases.

Key factors contributing to the swift growth ar the rapid development in fast growing Asian economies such as India, China, and others, the increasing healthcare expenditure to improve R&D activities, rapid proliferation of advanced diagnostic technologies, and the increasing awareness about the genetic and molecular screening tests; these crucial factors are expected to synergistically propel the market growth over the forecast period.

The global molecular cytogenetics market is dominated by players such as Abbott Laboratories Inc., Illumina, Inc., Agilent Technologies, Inc., Applied Spectral Imaging, Inc., PerkinElmer, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., and others.


Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Industry Outlook
3.1 Market segmentation
3.2 Market size and growth prospects, 2012 - 2022
3.3 Molecular cytogenetics market dynamics
3.3.1 Market driver analysis
3.3.2 Introduction of advanced technologies
3.3.3 Rising incidence of cancer
3.3.4 Advent of Next Generation Sequencing
3.3.5 Market restraint analysis
3.3.6 Issues with medical reimbursement
3.4 Key Opportunities Prioritized: Technology
3.5 Industry analysis Porter’s
3.6 Molecular cytogenetics PESTEL Analysis
Chapter 4 Molecular Cytogenetics Technology Outlook
4.1 Molecular cytogenetics revenue share by technology, 2014 & 2022
4.2 FISH
4.2.1 FISH market, 2012 - 2022 (USD Million)
4.3 CGH
4.3.1 CGH market, 2012 - 2022 (USD Million)
Chapter 5 Molecular Cytogenetics Application Outlook
5.1 Molecular cytogenetics revenue share by application, 2014 & 2022
5.2 Genetic disorders
5.2.1 Genetic disorders market, 2012 - 2022 (USD Million)
5.3 Cancer
5.3.1 Cancer market, 2012 - 2022 (USD Million)
5.4 Personalized medicine
5.4.1 Personalized medicine market, 2012 - 2022 (USD Million)
5.5 Others (Neurological, Cardiovascular, and Infectious Diseases)
5.5.1 Others market, 2012 - 2022 (USD Million)
Chapter 6 Molecular Cytogenetics Regional Outlook
6.1 Molecular cytogenetics market share, by region, 2014 & 2022
6.2 North America
6.2.1 North America molecular cytogenetics market 2012 - 2022 (USD Million)
6.3 Europe
6.3.1 Europe molecular cytogenetics market, 2012 - 2022 (USD Million)
6.4 Asia Pacific
6.4.1 Asia Pacific molecular cytogenetics market, 2012 - 2022 (USD Million)
6.5 RoW
6.5.1 RoW molecular diagnostics market, 2012 - 2022 (USD Million)
Chapter 7 Competitive Landscape
7.1 Affymetrix, Inc.
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Agilent Technologies, Inc.
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Applied Spectral Imaging, Inc.
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 BI Biological Industries, Inc.
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Abbott Laboratories
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives
7.6 Bio-Rad Laboratories, Inc.
7.6.1 Company Overview
7.6.2 Financial Performance
7.6.3 Product Benchmarking
7.6.4 Strategic Initiatives
7.7 Thermo Fisher Scientific, Inc.
7.7.1 Company Overview
7.7.2 Financial Performance
7.7.3 Product Benchmarking
7.7.4 Strategic Initiatives
7.8 Oxford Gene Technologies, Inc.
7.8.1 Company Overview
7.8.2 Financial Performance
7.8.3 Product Benchmarking
7.8.4 Strategic Initiatives
7.9 CytoTest, Inc.
7.9.1 Company Overview
7.9.2 Financial Performance
7.9.3 Product Benchmarking
7.9.4 Strategic Initiatives
7.10 Cytognomix, Inc.
7.10.1 Company Overview
7.10.2 Financial Performance
7.10.3 Product Benchmarking
7.10.4 Strategic Initiatives
List of Tables
TABLE 1 Molecular Cytogenetics - Industry Snapshot & Key Buying Criteria, 2012 - 2022
TABLE 2 Global molecular cytogenetics market revenue, by technology, 2012 - 2022 (USD Million)
TABLE 3 Global molecular cytogenetics market revenue, by application, 2012 - 2022 (USD Million)
TABLE 4 Global molecular cytogenetics revenue, by region, 2012 - 2022 (USD Million)
TABLE 5 Molecular cytogenetics - Key market driver analysis
TABLE 6 Global cancer incidences in 2012
TABLE 7 North America cancer incidences in 2012
TABLE 8 Europe cancer incidences in 2012
TABLE 9 Asia cancer incidences in 2012
TABLE 10 Africa cancer incidences in 2012
TABLE 11 Australia and New Zealand cancer incidences in 2012
TABLE 12 Molecular cytogenetics - Key market restraint analysis
TABLE 13 North America molecular cytogenetics market, by technology, 2012 - 2022 (USD Million)
TABLE 15 Europe molecular cytogenetics market, by technology, 2012 - 2022 (USD Million)
TABLE 16 Europe molecular cytogenetics market, by application, 2012 - 2022 (USD Million)
TABLE 17 Asia Pacific molecular cytogenetics market, by technology, 2012 - 2022 (USD Million)
TABLE 18 Asia Pacific molecular cytogenetics market, by application, 2012 - 2022 (USD Million)
TABLE 19 RoW molecular diagnostics market, by technology, 2012 - 2022 (USD Million)
TABLE 20 RoW molecular diagnostics market, by application, 2012 - 2022 (USD Million)
List of Figures
FIG. 1 Molecular cytogenetics market segmentation
FIG. 2 Global molecular cytogenetics market, 2012 - 2022 (USD Million)
FIG. 3 Molecular cytogenetics market dynamics
FIG. 4 Key Opportunities Prioritized: Technology
FIG. 5 Molecular cytogenetics market Porter’s analysis
FIG. 6 Molecular cytogenetics PESTEL analysis
FIG. 7 Molecular cytogenetics revenue share by technology, 2014 & 2022
FIG. 8 FISH market, 2012 - 2022 (USD Million)
FIG. 9 CGH market, 2012 - 2022 (USD Million)
FIG. 10 Molecular cytogenetics revenue share by application, 2014 & 2022
FIG. 11 Genetic disorder market, 2012 - 2022 (USD Million)
FIG. 12 Cancer market, 2012 - 2022 (USD Million)
FIG. 13 Personalized medicine market, 2012 - 2022 (USD Million)
FIG. 14 Others market, 2012 - 2022 (USD Million)
FIG. 15 Molecular cytogenetics market share, by region, 2014 & 2022
FIG. 16 North America molecular cytogenetics market, 2012 - 2022 (USD Million)
FIG. 17 Europe molecular cytogenetics market, 2012 - 2022 (USD Million)
FIG. 18 Asia Pacific molecular cytogenetics market, 2012 - 2022 (USD Million)
FIG. 19 RoW molecular diagnostics market, 2012 - 2022 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report